Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Peritoneal Cancer ◽

Multicenter Phase ◽

Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5578 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5578-5578

Author(s):

Isabelle Ray-Coquard ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5567 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Nicole Concin ◽

Ioana Braicu ◽

Pierre Combe ◽

Isabelle Laure Ray-Coquard ◽

Florence Joly ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase Ii ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Frontiers in Oncology ◽

10.3389/fonc.2019.00832 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 2

Author(s):

Isabelle Ray-Coquard ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Multicenter Phase ◽

Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian, fallopian tube or primary peritoneal cancer

http://isrctn.org/> ◽

10.1186/isrctn32163062 ◽

2012 ◽

Author(s):

Lee Webber

Keyword(s):

Fallopian Tube ◽

Weekly Paclitaxel ◽

Peritoneal Cancer ◽

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.06.032 ◽

2021 ◽

Author(s):

Floor J. Backes ◽

Lai Wei ◽

Min Chen ◽

Kasey Hill ◽

Kyle Dzwigalski ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Weekly Paclitaxel ◽

Peritoneal Cancer

Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3468-5 ◽

2017 ◽

Vol 80 (6) ◽

pp. 1239-1247 ◽

Cited By ~ 3

Author(s):

Kiyoshi Yoshino ◽

Shoji Kamiura ◽

Takeshi Yokoi ◽

Ruriko Nakae ◽

Masami Fujita ◽

...

Keyword(s):

Phase I ◽

Combination Chemotherapy ◽

Peritoneal Cancer ◽

Resistant Refractory ◽

Multicenter Phase ◽

Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-3589-5 ◽

2018 ◽

Vol 82 (6) ◽

pp. 1087-1088

Author(s):

Michael Eichbaum ◽

Christine Eichbaum

Keyword(s):

Phase I ◽

Combination Chemotherapy ◽

Peritoneal Cancer ◽

Resistant Refractory ◽

Multicenter Phase ◽

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdu363 ◽

2014 ◽

Vol 25 (10) ◽

pp. 1988-1995 ◽

Cited By ~ 46

Author(s):

I.A. McNeish ◽

J.A. Ledermann ◽

L. Webber ◽

L. James ◽

S.B. Kaye ◽

...

Keyword(s):

Fallopian Tube ◽

Controlled Trial ◽

Weekly Paclitaxel ◽

Peritoneal Cancer ◽